Cost-Effectiveness Analysis of Anlotinib as Third- or Further-Line Treatment for Relapsed Small Cell Lung Cancer (SCLC) in China

作者：Jinhong Gong, Qian Wan, Jingjing Shang, Xiaodan Qian, Dan Su, Zhiqiang Sun, Guangjun Liu · 发表于：Advances in Therapy · 年份：2021 · DOI：10.1007/s12325-021-01889-2 · 被引用次数：21 · 研究领域：Lung Cancer Research Studies、Neutropenia and Cancer Infections、PARP inhibition in cancer therapy